Efficacy and Safety of Relacorilant in Patients With Adrenal Hypercortisolism: Results From a Phase 3 Study
Summary
- In GRADIENT, relacorilant led to clinically significant improvements in signs and symptoms of endogenous hypercortisolism, including improvements in blood pressure, hyperglycemia, and body weight/composition
- Greater reductions in systolic blood pressure were observed with relacorilant treatment in the subgroup of patients with 2 abnormal cortisol tests
- Relacorilant exhibited statistically significant improvements in hyperglycemia, weight loss, and decreased visceral adiposity in all patients
- Relacorilant was well tolerated, and many of the most common adverse events were consistent with cortisol withdrawal
- The safety profile of relacorilant was similar to that seen in previous trials in patients with endogenous hypercortisolism of all etiologies